This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
News: Publications

Commentary: Triglycerides and cardiovascular risk: apolipoprotein B holds the key

Thursday 21 February 2019   (0 Comments)
Share |

In a recent Mendelian randomization study, the clinical benefit from treatments that lower LDL cholesterol or triglycerides was shown to be proportional to the absolute reduction in apolipoprotein B- containing lipoprotein particles, irrespective of changes in plasma levels of LDL cholesterol or triglycerides. This study has important implications for the design of future trials of novel therapies targeting hypertriglyceridemia, as discussed in this commentary.

To the commentary by Jane K. Stock>>

Membership Software Powered by YourMembership  ::  Legal